Evidence map›Paper›PMID 24869801›Full record

ArticleJAMA dermatology2014

Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.

Antonia Valenzuela, Lorinda Chung, Livia Casciola-Rosen, David Fiorentino

Abstract read
In one paragraph

Article in JAMA dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Calcinosis in dermatomyositis: Origins and possible therapeutic avenues.Best practice & research. Clinical rheumatology · 2022
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Antonia ValenzuelaDivision of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California.
Lorinda ChungDivision of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California2Department of Dermatology, Stanford University School of Medicine, Stanford, California.
Livia Casciola-RosenDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
David FiorentinoDivision of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California2Department of Dermatology, Stanford University School of Medicine, Stanford, California.
Stanford University · USJohns Hopkins Medicine · US

Funding

Interferons and cytotoxic lymphocytes in dermatomyositis and cutaneous lupusR56AR062615 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CASCIOLA-ROSEN, LIVIA A, FIORENTINO, DAVID FRANKLIN · 2013 to 2013
$200k
NIAMS NIH HHS R56 AR062615
6 · The paper itself

Abstract

importancePrior studies have estimated that up to 20% of adults with dermatomyositis (DM) have calcinosis, which can lead to significant morbidity. Identification of risk factors may provide a better understanding of the pathogenesis and ultimately therapy for this difficult clinical problem. Risk factors for calcinosis in adults with DM have not been extensively studied.

objectivesTo determine the prevalence of calcinosis and to identify associated clinical features in a cohort of extensively phenotyped adults with DM. DESIGN, SETTING, AND

participantsA cross-sectional study of 126 patients diagnosed as having DM from January 1, 2006, through January 1, 2013, was performed. Patients were adults (≥18 years of age) attending the Stanford University Medical Center clinic. MAIN OUTCOMES AND MEASURES: Calcinosis, defined as the presence of calcium deposition in the skin and subcutaneous tissues on physical examination.

resultsFourteen patients (11.1%) had calcinosis, with the extremities most commonly involved. Patients with vs those without calcinosis had a longer disease duration (median, 6.9 years; range, 2.4-18.1; vs median, 3.9 years; range, 0.2-19.2 years; P = .003) and more fingertip ulcers (50.0% vs 9.3%, P < .001). An association between calcinosis and both interstitial lung disease and anti-MDA-5 autoantibodies was identified, but this association did not persist in multivariate models that adjusted for fingertip ulcers. Fingertip ulcers and disease duration were strongly associated with calcinosis in all multivariate models, independent of the underlying autoantibody present. Autoantibodies to NXP-2 were associated with calcinosis (odds ratio, 15.52; 95% CI, 2.01-119.90), whereas anti-transcriptional intermediary factor 1-γ antibodies were protective (odds ratio, 0.2; 95% CI, 0.01-0.99) in multivariate analyses that adjusted for fingertip ulcers and other covariates. CONCLUSIONS AND RELEVANCE: Calcinosis was a relatively uncommon clinical feature in our cohort of adults with DM. Our data suggest that calcinosis is positively associated with longer disease duration, fingertip ulcers, and NXP-2 autoantibodies and negatively associated with transcriptional intermediary factor 1-γ antibodies. A common vascular mechanism may underlie the development of both calcinosis and fingertip ulcers in patients with DM.

Indexed as

Adenosine TriphosphatasesAdultAutoantibodiesCalcinosisCross-Sectional StudiesDEAD-box RNA HelicasesDermatomyositisDNA-Binding ProteinsFemaleFingersHumansInterferon-Induced Helicase, IFIH1Lung Diseases, InterstitialMaleMiddle AgedPhenotypeAdenosine TriphosphatasesAutoantibodiesDEAD-box RNA HelicasesDNA-Binding ProteinsIFIH1 protein, humanInterferon-Induced Helicase, IFIH1MORC3 protein, humanRibonucleoproteinsSS-A AntigenTranscription FactorsTRIM33 protein, human

Identifiers

PMID24869801
PMCPMC4351704
OpenAlexW1970844055

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.